A new paradigm for the diagnosis and management of unknown primary tumors of the head and neck: A role for transoral robotic surgery
Vikas Mehta(King's College London), Umamaheswar Duvvuri(City University of New York), Paul J. Johnson(Eye and Ear Foundation), Melonie A. Nance(Anna Needs Neuroblastoma Answers), Robert L. Ferris(University of Pittsburgh), Jonas T. Johnson(University of Pittsburgh), Seungwon Kim(UPMC Hillman Cancer Center), Andrew B. Tassler(Cornell University)
Cited by 167
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression
|Oral Oncology|2018|802
Immune Landscape of Viral- and Carcinogen-Driven Head and Neck Cancer
|Immunity|2020|688
Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
|The Lancet Oncology|2021|618
Frequent Mutation of the PI3K Pathway in Head and Neck Cancer Defines Predictive Biomarkers
|Cancer Discovery|2013|590